Detail Information of Exogenous Modulation
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0010 Transporter Info | ||||
| Gene Name | SLC22A1 | ||||
| Transporter Name | Organic cation transporter 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
|---|---|---|---|---|---|
Approved Drug |
|||||
Quinine |
7 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.7 microM) | [1] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 13 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 5.7 microM) | [3] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OCT1 | ||||
DT Modulation 4 |
Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 22.9 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 5 |
Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 17.5 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 6 |
Quinine inhibits the transportation of YM155 by SLC22A1 (IC50 = 7.11 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 7 |
Quinine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Verapamil |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Verapamil inhibits the transportation of Metformin by SLC22A1 (IC50 = 0.62 microM) | [10] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Verapamil inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.9 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 3 |
Verapamil inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.23 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 4 |
Verapamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Metformin |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1231 microM) | [1] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 493 microM) | [11] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Metformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2820 microM) | [11] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 4 |
Metformin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] , [12] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Estradiol |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 5.73 microM) | [13] | |||
Affected Drug/Substrate |
1-Methyl-4-phenylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Estradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Estradiol inhibits the activity of SLC22A1 | [13] | |||
Repaglinide |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Repaglinide inhibits the transportation of Metformin by SLC22A1 (IC50 = 1.6 microM) | [14] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OCT1 | ||||
DT Modulation 2 |
Repaglinide inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.8 microM) | [14] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OCT1 | ||||
DT Modulation 3 |
Repaglinide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ranitidine |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 33 microM) | [1] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Ranitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clonidine |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clonidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.5 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Clonidine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 0.55 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 3 |
Clonidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cimetidine |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cimetidine inhibits the transportation of YM155 by SLC22A1 (IC50 = 149 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Cimetidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] , [12] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Cimetidine inhibits the activity of SLC22A1 | [11] | |||
Prazosin |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Prazosin inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.56 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Prazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Prazosin inhibits the activity of SLC22A1 | [13] , [16] | |||
Nicotine polacrilex |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Nicotine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Nicotine inhibits the transportation of Tetraethylammonium by SLC22A1 | [15] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 3 |
Nicotine inhibits the activity of SLC22A1 | [17] | |||
Vecuronium |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Vecuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (Ki = 120 microM) | [18] | |||
Affected Drug/Substrate |
1-Methyl-4-phenylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Vecuronium inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 232 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Phenoxybenzamine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 2.72 microM) | [13] | |||
Affected Drug/Substrate |
1-Methyl-4-phenylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Phenoxybenzamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Progesterone |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 3.05 microM) | [13] | |||
Affected Drug/Substrate |
1-Methyl-4-phenylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Progesterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Disopyramide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Disopyramide inhibits the transportation of 4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) by SLC22A1 (IC50 = 81.7 microM) | [6] | |||
Affected Drug/Substrate |
4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Disopyramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Amitriptyline |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Amitriptyline inhibits the transportation of Metformin by SLC22A1 (IC50 = 6.99 microM) | [10] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Amitriptyline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Glyburide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Glibenclamide inhibits the transportation of Metformin by SLC22A1 (IC50 = 199 microM) | [10] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Glibenclamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Simvastatin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Simvastatin inhibits the transportation of Metformin by SLC22A1 (IC50 = 89 microM) | [10] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Simvastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Famotidine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Famotidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM) | [1] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Famotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Atropine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Atropine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.2 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Atropine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Amantadine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Amantadine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 236 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Amantadine inhibits the transportation of YM155 by SLC22A1 (IC50 = 39.6 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Memantine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Memantine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 3.7 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Memantine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ritonavir |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ritonavir inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 14 microM) | [21] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Ritonavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 5.18 microM) | [22] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Acebutolol |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acebutolol inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 95.8 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 2 |
Acebutolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Indinavir |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Indinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 61.7 microM) | [22] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
DT Modulation 2 |
Indinavir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Procainamide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Procainamide inhibits the transportation of YM155 by SLC22A1 (IC50 = 51.3 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Procainamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tubocurarine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tubocurarine inhibits the transportation of YM155 by SLC22A1 (IC50 = 62.4 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Tubocurarine inhibits the activity of SLC22A1 | [23] | |||
Pancuronium |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pancuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 | [18] | |||
Affected Drug/Substrate |
1-Methyl-4-phenylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Pancuronium inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Amiloride |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Amiloride inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Amiloride inhibits the activity of SLC22A1 | [23] | |||
Rifampicin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Rifampicin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Profenamine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ethopropazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [12] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Ethopropazine inhibits the transportation of Metformin by SLC22A1 | [12] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tacrine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [12] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Tacrine inhibits the transportation of Metformin by SLC22A1 | [12] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Vitamin B1 |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Vitamin B1 inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [12] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Vitamin B1 inhibits the transportation of Tetraethylammonium by SLC22A1 | [15] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Rifampin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Rifampicin induces the activity of SLC22A1 | [24] | |||
Pioglitazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pioglitazone inhibits the transportation of Metformin by SLC22A1 (IC50 = 185 microM) | [10] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Butylscopolamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Diphenhydramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 3.4 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cocaine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cocaine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 85 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Dextroamphetamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 202 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ketamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ketamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 114.5 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Pentamidine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16.4 microM) | [3] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OCT1 | ||||
Midazolam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Midazolam inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 3.7 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Nelfinavir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Nelfinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.8 microM) | [22] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Saquinavir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Saquinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 8.26 microM) | [22] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Lindane |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Lindane inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 1.52 microM) | [27] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human hepatoma HepaRG cells-OCT1 | ||||
Benzyl alcohol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Benzyl alcohol inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.018 microM) | [30] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Acarbose |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acarbose inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Acetaminophen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acetaminophen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Acetylcysteine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acetylcysteine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Acyclovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acyclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Allopurinol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Allopurinol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ampicillin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ampicillin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Amsacrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Amsacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Apomorphine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Apomorphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Aspirin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Aspirin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Atenolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Atenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Azathioprine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Azathioprine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Baclofen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Baclofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Budesonide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Budesonide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Buspirone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Buspirone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Caffeine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Caffeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Candesartan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Candesartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Captopril |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Captopril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Carbamazepine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Carbamazepine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Carisoprodol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Carisoprodol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Celecoxib |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Celecoxib inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cephalexin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cephalexin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cetirizine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cetirizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Chloramphenicol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chloramphenicol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Chloroquine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chloroquine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Chlorpromazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chlorpromazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Chlorprothixene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chlorprothixene inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Chlorzoxazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chlorzoxazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Citalopram |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Citalopram inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clemastine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clemastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clindamycin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clindamycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clodronic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clodronate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clomipramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clomipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clotrimazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clotrimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Clozapine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Clozapine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Codeine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Codeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Colchicine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Colchicine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cyclophosphamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cyclophosphamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cyclosporine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cyclosporine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cyproterone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cyproterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cysteamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cysteamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Denopamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Denopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Desipramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Desipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Diazepam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Diazepam inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Diclofenac |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Diclofenac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Digoxin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Digoxin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Diltiazem |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Diltiazem inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Dopamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Doxazosin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Doxazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Doxycycline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Doxycycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Efavirenz |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Efavirenz inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Eflornithine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Eflornithine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Enalapril |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Enalapril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ergotamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ergotamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ergotidine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ergotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Erythromycin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Erythromycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Esmolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Esmolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Etoposide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Etoposide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Felodipine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Felodipine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Fenofibrate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fenofibrate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Fentanyl |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fentanyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Fluorouracil |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fluorouracil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Fluphenazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fluphenazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Flutamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Flutamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Folic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Folic acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Furosemide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Furosemide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Gabapentin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Gabapentin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ganciclovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ganciclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Glipizide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Glipizide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Glucosamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Glucosamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Haloperidol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Haloperidol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Hydralazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Hydralazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Hydrochlorothiazide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Hydrochlorothiazide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ibuprofen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ibuprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Imipramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Imipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ketoconazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ketoconazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ketoprofen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ketoprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Levodopa |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Levodopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Levofloxacin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Levofloxacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Levothyroxine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Levothyroxine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Lidocaine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Lidocaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Loperamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Loperamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Loratadine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Loratadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Mannitol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Mannitol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Meclizine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Meclizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Mepenzolate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Mepenzolate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Methimazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Methimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Methotrexate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Methotrexate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Methyldopa |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Methyldopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Metoclopramide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Metoclopramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Metoprolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Metoprolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Mianserin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Mianserin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Morphine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Morphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Naltrexone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Naltrexone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Nandrolone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Nandrolone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Ondansetron |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Ondansetron inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Orciprenaline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Orciprenaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Orphenadrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Orphenadrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Oxprenolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Oxprenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Paclitaxel |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Paclitaxel inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Papaverine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Papaverine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Phenobarbital |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phenobarbital inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Phenytoin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phenytoin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Pilocarpine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pilocarpine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Pravastatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pravastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Prednisone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Prednisone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Probenecid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Probenecid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Prochlorperazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Prochlorperazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Promazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Promazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Promethazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Promethazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Propafenone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Propafenone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Propofol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Propofol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Propranolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Propranolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Risperidone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Risperidone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Scopolamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Scopolamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Sotalol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sotalol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Spironolactone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Spironolactone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Sulfasalazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sulfasalazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Sulindac |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sulindac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tamoxifen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tamoxifen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Terazosin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Terazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Terbutaline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Terbutaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tetracycline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tetracycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Theophylline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Theophylline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Timolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Timolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tramadol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tramadol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Trihexyphenidyl |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Trihexyphenidyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Trimethoprim |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Trimethoprim inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Trimipramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Trimipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Troglitazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Troglitazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Valproic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Valproic Acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Vancomycin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Vancomycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Vinblastine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Vinblastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Warfarin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Warfarin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Zanamivir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Zanamivir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Zidovudine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Zidovudine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Dolutegravir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dolutegravir inhibits the transportation of Metformin by SLC22A1 | [31] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Caspofungin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Caspofungin inhibits the transportation of Tetraethyl by SLC22A1 | [32] | |||
Affected Drug/Substrate |
Tetraethyl | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Pindolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pindolol inhibits the transportation of Tetraethylammonium by SLC22A1 | [15] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Rocuronium |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Rocuronium inhibits the transportation of Tributylmethylammonium by SLC22A1 | [33] | |||
Affected Drug/Substrate |
Tributylmethylammonium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
Beclomethasone dipropionate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Beclomethasone dipropionate inhibits the transportation of Agonist salbutamol by SLC22A1 | [35] | |||
Affected Drug/Substrate |
Agonist salbutamol | Modulation Type | Inhibition | ||
Eltrombopag |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Eltrombopag inhibits the transportation of Tetraethylammonium by SLC22A1 | [9] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Decitabine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Decitabine inhibits DNA methyltransferase, which then enhances Sorafenib's transportation via downregulating the hypermethylation in SLC22A1's promoter | [36] | |||
Affected Drug/Substrate |
Sorafenib | Modulation Type | Inducer | ||
Cell System |
Human embryonal rhabdomyosarcoma cells | ||||
Rosiglitazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Rosiglitazone increases the expression of SLC22A1 | [37] | |||
Regulation Mechanism |
via enhancement of Peroxisome proliferator-activated receptor gamma (PPARG) | Transcription Factor Info | |||
Cell System |
Human vascular smooth muscle cells | ||||
Chenodeoxycholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chenodeoxycholic acid inhibits the expression of SLC22A1 | [38] | |||
Regulation Mechanism |
via the inhibition of Hepatocyte nuclear factor 4-alpha (HNF4A) | Transcription Factor Info | |||
Cell System |
Human adult hepatocellular carcinoma cells (Huh7) | ||||
Indomethacin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Indomethacin inhibits the activity of SLC22A1 | [39] | |||
Mefenamic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Mefenamic Acid inhibits the activity of SLC22A1 | [39] | |||
Urethane |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Urethane increases the expression of SLC22A1 | [40] | |||
Tretinoin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tretinoin increases the expression of SLC22A1 | [41] | |||
Crizotinib |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Crizotinib inhibits the activity of SLC22A1 | [42] | |||
Carvedilol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Carvedilol inhibits the activity of SLC22A1 | [43] | |||
Dexamethasone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dexamethasone induces the activity of SLC22A1 | [44] | |||
Insulin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Insulin induces the activity of SLC22A1 | [45] | |||
Pyrazinamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Pyrazinamide inhibits the activity of SLC22A1 | [46] | |||
Itraconazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Itraconazole inhibits the activity of SLC22A1 | [47] | |||
Sparfloxacin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sparfloxacin inhibits the activity of SLC22A1 | [48] | |||
Drug in Phase 2/3 Trial |
|||||
MJ-13105 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Bucindolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Sodium butyrate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Butyrate inhibits histone deacetylase, which then enhances Sorafenib's transportation via increasing the histone acethylation level of SLC22A1 | [36] | |||
Affected Drug/Substrate |
Sorafenib | Modulation Type | Inducer | ||
Cell System |
Human embryonal rhabdomyosarcoma cells | ||||
Drug in Phase 3 Trial |
|||||
Anisodine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Anisodine inhibits the activity of SLC22A1 (IC50 = 12.9 microM) | [25] | |||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Melagatran |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Melagatran inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Drug in Phase 2 Trial |
|||||
YM155 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
YM155 inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 23.8 microM) | [5] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Gallopamil |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Gallopamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
2-Methoxyestradiol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
2-Methoxyestradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Bisphenol A inhibits the activity of SLC22A1 | [52] | |||
Drug in Phase 1/2 Trial |
|||||
Sodium taurocholate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sodium taurocholate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Drug in Phase 1 Trial |
|||||
Sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Sodium arsenite inhibits the expression of SLC22A1 | [53] | |||
Drug in Preclinical Test |
|||||
N-methylpyridinium |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
N-methylpyridinium inhibits the transportation of YM155 by SLC22A1 (IC50 = 30.4 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Epinephrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Epinephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Beta-carboline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Beta-carboline inhibits the activity of SLC22A1 | [54] | |||
Discontinued Drug |
|||||
Dizocilpine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 80.5 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Antiparasitics |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 7.4 microM) | [3] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OCT1 | ||||
Acecainide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Acecainide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Investigative Drug |
|||||
Tetraethylammonium |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 216 microM) | [1] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 469.7 microM) | [3] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OCT1 | ||||
DT Modulation 3 |
Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 158 microM) | [7] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 4 |
Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 167 microM) | [8] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 5 |
Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 | [9] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Decynium 22 |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.9 microM) | [8] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OCT1 | ||||
DT Modulation 2 |
Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.73 microM) | [4] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OCT1 | ||||
Corticosterone |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Corticosterone inhibits the transportation of YM155 by SLC22A1 (IC50 = 8.89 microM) | [5] | |||
Affected Drug/Substrate |
YM155 | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Corticosterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Phencyclidine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 4.4 microM) | [20] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Androstenedione |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
4-Androstene-3-17-Dione inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Agmatine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Agmatine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Arcaine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Arcaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Choline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Choline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Normetanephrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Normetanephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Phenazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phenazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Beta-naphthoflavone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Beta-naphthoflavone inhibits the expression of SLC22A1 | [50] | |||
Drug Withdrawn |
|||||
Phenformin |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phenformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 13 microM) | [11] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Phenformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 23 microM) | [11] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 3 |
Phenformin inhibits the activity of SLC22A1 | [11] | |||
Etilefrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 447 microM) | [2] | |||
Affected Drug/Substrate |
N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Terfenadine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Terfenadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 | [6] | |||
Affected Drug/Substrate |
4-(4-(dimethylamino)styryl)-N-methylpyridinium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Natural Product |
|||||
Fenamiphos |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fenamiphos inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 27.5 microM) | [19] | |||
Affected Drug/Substrate |
4',6'-diamidino-2-phenylindole | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Fenamiphos inhibits the transportation of Dopamine by SLC22A1 (IC50 = 9.2 microM) | [19] | |||
Affected Drug/Substrate |
Dopamine | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Phosmet |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Phosmet inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 10.4 microM) | [19] | |||
Affected Drug/Substrate |
4',6'-diamidino-2-phenylindole | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
DT Modulation 2 |
Phosmet inhibits the transportation of Dopamine by SLC22A1 (IC50 = 7.1 microM) | [19] | |||
Affected Drug/Substrate |
Dopamine | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Citreoverdine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Citreoverdine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Dieldrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Dieldrin inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.9 microM) | [27] | |||
Affected Drug/Substrate |
Tetraethylammonium | Modulation Type | Inhibition | ||
Cell System |
Human hepatoma HepaRG cells-OCT1 | ||||
Allethrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Allethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 2.6 microM) | [28] | |||
Affected Drug/Substrate |
Verapamil | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Tetramethrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tetramethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 4.9 microM) | [28] | |||
Affected Drug/Substrate |
Verapamil | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OCT1 | ||||
Cigarette smoke condensate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cigarette smoke condensate inhibits the transportation of Verapamil by SLC22A1 (IC50 = 12.5 microM) | [29] | |||
Affected Drug/Substrate |
Verapamil | Modulation Type | Inhibition | ||
Cell System |
Human hepatoma HepaRG cells-OCT1 | ||||
Green tea |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Green tea inhibits the transportation of Metformin by SLC22A1 | [34] | |||
Affected Drug/Substrate |
Metformin | Modulation Type | Inhibition | ||
Cell System |
Human enterocyte-like 2 cell (Caco-2)-OCT1 | ||||
Hyperforin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Hyperforin inhibits the expression of SLC22A1 | [49] | |||
Regulation Mechanism |
via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2) | Transcription Factor Info | |||
Cell System |
Human hepatoblastoma cells (HepG2) | ||||
Particulate Matter |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Particulate Matter inhibits the expression of SLC22A1 | [51] | |||
Methyleugenol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Methyleugenol inhibits the expression of SLC22A1 | [56] | |||
Tobacco Smoke Pollution |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tobacco Smoke Pollution inhibits the expression of SLC22A1 | [58] | |||
Environmental toxicant |
|||||
Tetrabromobisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Tetrabromobisphenol A inhibits the activity of SLC22A1 | [52] | |||
Polychlorinated dibenzodioxin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Polychlorinated dibenzodioxin inhibits the expression of SLC22A1 | [29] | |||
Mycotoxins |
|||||
Aflatoxin B1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 = 64.4 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Alpha-zearalenol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A1 (IC50 = 1.7 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Citrioveridine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Citrioveridine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Cyclopiazonic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Cyclopiazonic acid inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Fumonisin B1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Fumonisin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Patulin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Patulin inhibits the transportation of Organic cation by SLC22A1 | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Gliotoxin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Gliotoxin inhibits the transportation of Organic cation by SLC22A1 (IC50 = 584 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Zearalenone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Zearalenone inhibits the transportation of Organic cation by SLC22A1 (IC50 = 0.62 microM) | [26] | |||
Affected Drug/Substrate |
Organic cation | Modulation Type | Inhibition | ||
Cell System |
The Proximal Tubule (S2) Cells-OCT1 | ||||
Carcinogen |
|||||
Benzo(a)pyrene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Benzo(a)pyrene inhibits the expression of SLC22A1 | [56] | |||
Pesticide/Insecticide |
|||||
Endosulfan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Endosulfan inhibits the expression of SLC22A1 | [27] | |||
Heptachlor |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Heptachlor inhibits the activity of SLC22A1 | [27] | |||
Imidacloprid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Imidacloprid increases the activity of SLC22A1 | [55] | |||
Health and Environmental Toxicant |
|||||
Chlordan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Chlordan inhibits the activity of SLC22A1 | [27] | |||
Perfluorooctane sulfonic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation 1 |
Perfluorooctane sulfonic acid inhibits the expression of SLC22A1 | [57] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.